AI, Bioregenerative Medicine, CMOS Device Manufacturing

Sotai Biosystems

Building a semiconductor-enabled platform to make cell transfection and cell engineering more reproducible, less damaging, and easier to scale.

AI

Payload candidates, condition recommendations, and measurement-informed guidance for EP function parameters.

Bioregenerative Medicine

Development workflows for cell delivery, functional evaluation, and later efficacy validation.

CMOS Device Manufacturing

CMOS-compatible electrodes and dielectric structures checked through electric-field and potential simulation.

Company slogan — A / B / C

AI, bioregenerative medicine, and CMOS device manufacturing

Sotai's formal A/B/C positioning connects AI-assisted EP development, bioregenerative medicine workflows, and CMOS-compatible device manufacturing.

AI

AI generates payload candidates and condition recommendations, then uses measurement feedback to guide changes to EP function parameters. Engineering and biology teams must confirm every output.

Bioregenerative Medicine

This application focus defines the development workflow for cell delivery, functional evaluation, and later efficacy validation.

CMOS Device Manufacturing

CMOS-compatible processes integrate electrode and dielectric structures. Electric-field and electric-potential simulations check designs that add EP functions.

Platform

From bulk electroporation to controllable cell-scale processing.

Sotai combines CMOS biochips, microelectrode arrays, pulse-control electronics, and biological readouts into a reproducible transfection feedback loop.

CMOS Biochip

Mature semiconductor manufacturing can support device-to-device consistency, scalable production, and lower long-term cost.

Microelectrode Arrays

Localized electric-field control enables more precise interaction among field strength, cell state, and payload delivery.

Smart Pulse Control

Standardized pulse delivery is designed to reduce operator variation and improve repeatability across experiments.

Low-Damage Workflow

The platform balances delivery efficiency with viability, recovery, expansion potential, and downstream cell function.

Three-chart summary of a CMOS biochip-based low-damage cell transfection system
Three-chart summary of the CMOS biochip platform, adaptive low-damage transfection workflow, and application scope.

AI relevance

Structured biological process data for AI-driven optimization.

Sotai is designed to connect chip behavior, pulse parameters, cell response, payload type, transfection efficiency, viability, recovery, and functional outcomes.

  • Cell type and payload-aware parameter search
  • Efficiency, viability, and recovery as optimization objectives
  • Experiment tracking for reproducible process development
  • Future acceleration with GPU-enabled modeling and analytics
AI-EP-Biosensor system diagram from electrochemical sensing to smart healthcare applications

Regenerative Medicine Applications

Cell-engineering tools for regenerative medicine workflows.

Sotai is building a semiconductor-enabled platform for research and co-development involving stem cells, iPSCs, T/NK immune cells, and non-viral delivery.

Future cell pilots are expected to evaluate transfection efficiency, cell viability, viable-cell recovery, and batch-to-batch reproducibility.

Research status: These applications are future research and co-development directions. They do not indicate completed therapeutic, clinical, safety, or medical-device validation.

Stem Cells & iPSCs

Engineering workflows for gene delivery and viable-cell recovery.

T/NK Cell Engineering

Chip, interface, and data requirements for non-viral transfection or editing workflows.

Non-viral Delivery & Gene Editing

Process development for DNA, mRNA, proteins, and CRISPR/Cas payloads.

Hospitals & CRO/CDMO

Batch-to-batch reproducibility, closed-operation concepts, and process-data traceability.

Company

Taiwan-incorporated biomedical technology startup.

Sotai Biosystems combines AI-assisted EP development, bioregenerative medicine application workflows, and CMOS-compatible device manufacturing.

Stage Early platform validation
Financing need USD 2M / NT$50-60M
Seeking Strategic partners, AI infrastructure, CMOS ecosystem access

Contact

Build AI-driven cell engineering infrastructure with Sotai.

We welcome discussion with startup programs, strategic investors, semiconductor partners, healthcare AI teams, translational research groups, and biomanufacturing collaborators.

Executive Contacts

Dr. Bronte Sun
Chief Executive Officer
bronte@sotaibiosystems.com.tw
+886932308469

Dr. Chun-Lung Lien
Founder / Business Contact

andrew@sotaibiosystems.com.tw
+886-905-936-000

Email Sotai